What is the evidence base for DSIP (Intranasal)?

DSIP (Intranasal)'s evidence base sits at preclinical. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The body composition / training interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What route should I use for DSIP (Intranasal)?

DSIP (Intranasal) is delivered by intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

How long until I see results from DSIP (Intranasal)?

Acute effects from DSIP (Intranasal) appear within the first week for downstream physiological adaptation. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the regulatory status of DSIP (Intranasal)?

DSIP (Intranasal) regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level preclinical. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does DSIP (Intranasal)'s half-life affect dosing?

DSIP (Intranasal) has a plasma half-life of Rapid CNS uptake via olfactory route, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1 spray before sleep dosing at 100-300 mcg per dose explains the typical onset timeline for anabolic and recovery endpoints.

Home/ Compounds/ DSIP (Intranasal)

DSIP (Intranasal)

Body Composition

Body composition response to DSIP (Intranasal) is proportional to training stimulus and nutritional input. Intranasal DSIP for direct CNS delivery via the olfactory pathway — bypasses systemic circulation and acts on sleep architecture faster than subcutaneous. The compound contributes to the anabolic substrate, recovery window, or structural-adaptation layer depending on where its primary pharmacology acts. For trained athletes, the typical 8-12 week DSIP (Intranasal) cycle produces visible composition shifts at week 4-8 with the standard 100-300 mcg 1 spray before sleep dose.

Body Composition / Training Applications

HyperplasiaStrengthFat LossWorkout RecoveryJoint Health

Key Takeaways

Body composition lens: response to DSIP (Intranasal) is proportional to training stimulus and nutritional adequacy.
Mechanism: Same DSIP molecule delivered intranasally.
Body composition dose: 100-300 mcg 1 spray before sleep via intranasal; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by DSIP (Intranasal).

Anabolic substrate and protein synthesis

DSIP (Intranasal)'s relevance to body composition depends on where in the anabolic cascade it acts. It acts on adjacent rather than directly anabolic pathways, but the contribution to recovery, connective tissue, and inflammatory tone produces measurable body-composition effects in trained users. The downstream effect on body composition is dose- and training-dependent.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. DSIP (Intranasal) with a Rapid CNS uptake via olfactory route half-life of Rapid CNS uptake via olfactory route is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Hyperplasia and structural adaptation

Where DSIP (Intranasal) demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Body Composition / Training Applications

Training Performance

The body composition community converges on DSIP (Intranasal) for training performance with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Cardiovascular Conditioning

For cardiovascular conditioning, DSIP (Intranasal) integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Injury Recovery

Injury Recovery responds to DSIP (Intranasal) with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Endurance

The body composition community converges on DSIP (Intranasal) for endurance with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	60-300 mcg	4–6 weeks initial cycle
Body Composition focus	Intranasal	100-300 mcg	1 spray before sleep
Maintenance phase	Intranasal	70-300 mcg	Ongoing with periodic pauses

Dose timing for DSIP (Intranasal) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

DSIP (Intranasal) + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with DSIP (Intranasal)'s mechanism in body composition / training protocols.
DSIP (Intranasal) + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with DSIP (Intranasal)'s mechanism in body composition / training protocols.
DSIP (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with DSIP (Intranasal)'s mechanism in body composition / training protocols.
DSIP (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with DSIP (Intranasal)'s mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical

Excellent tolerability. Mild nasal irritation possible.

Lens-specific safety considerations for body composition / training use of DSIP (Intranasal): Excellent tolerability. Mild nasal irritation possible. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

DSIP (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
DSIP (Intranasal)	Neuropeptide (sleep, intranasal)	Rapid CNS uptake via olfactory route	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Can I use DSIP (Intranasal) alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

How does DSIP (Intranasal) compare to AAS for body composition?

Peptide therapeutics including DSIP (Intranasal) produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Should I cycle DSIP (Intranasal)?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

Will DSIP (Intranasal) actually increase lean mass?

DSIP (Intranasal)'s effect on body composition depends on which dimension of the anabolic cascade it engages. Direct anabolic pathway engagement is not the principal mechanism, but contributions to recovery, connective tissue, and inflammatory tone produce measurable body-composition shifts in trained users. Effect size is proportional to training stimulus and nutritional adequacy.

What does DSIP (Intranasal) stack well with?

For body composition / training protocols, DSIP (Intranasal) pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from DSIP (Intranasal)'s primary mechanism (Same DSIP molecule delivered intranasally), producing additive or synergistic effects rather than receptor competition.

Clinical Protocol

Start a DSIP (Intranasal) Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified DSIP (Intranasal) and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: Rapid CNS uptake via olfactory route
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for DSIP (Intranasal)

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised